Use of sulfamate derivatives for treating impulse control disorders

• US 6,323,236 B2
• Filed: 02/18/2000
• Issued: 11/27/2001
• Est. Priority Date: 02/24/1999
• Status: Expired due to Term

• Current Assignee: University of Cincinnati
• Original Assignee: University of Cincinnati
• Inventors: McElroy, Susan
• Primary Examiner(s): Jarvis, William R. A.
• Application Number:
  US09/506,991
• Publication Number:
  US 20010023254A1
• Time in Patent Office: 648 Days
• Field of Search: 514/455, 514/439, 514/459, 514/463
• US Class Current: 514/439
• CPC Class Codes: A61K 31/18 Sulfonamides compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63
• CPC Class Codes: A61K 31/351 not condensed with another ring
• CPC Class Codes: A61K 31/36 Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• CPC Class Codes: A61K 31/385 having two or more sulfur atoms in the same ring
• CPC Class Codes: A61K 31/7024 Esters of saccharides
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 25/32 Alcohol-abuse
• CPC Class Codes: A61P 25/34 Tobacco-abuse

Abstract

Impulse Control Disorders (ICD'"'"'s) are characterized by harmful behaviors performed in response to irresistible impulses. The essential feature of an ICD is the failure to resist an impulse, drive, or temptation and to perform an act that is harmful to the person or to others. The present invention comprises methods for the treatment or prevention of ICD'"'"'s using a class of sulfamates of the following formula:

wherein X is CH₂ or oxygen, and R₁, R₂, R₃, R₄ and R₅ are as herein defined. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention are also disclosed.

Claims

1. A method for treating an Impulse Control Disorder comprising administering to a mammal afflicted with such condition a therapeutically effective amount for treating such condition of a compound of the formula I:

wherein

X is CH₂ or oxygen;

R₁ is hydrogen or alkyl; and

R₂, R₃, R₄ and R₅ are independently hydrogen or lower alkyl and, when X is CH₂, R₄ and R₅ may be alkene groups joined to form a benzene ring and, when X is oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of the follow formula (II);

 

wherein

R₆ and R₇ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring;

wherein the Impulse Control Disorder is selected from the group consisting of intermittent explosive disorder (ED), kleptomania, pathological gambling, pyromania, trichotillomania, compulsive buying or shopping, repetitive self-mutilation, nonparaphilic sexual addictions, severe nail biting, compulsive skin picking, personality disorders with impulsive features, attention deficit/hyperactivity disorder, Binge Eating Disorder, bulimia nervosa, anorexia nervosa with binge eating and substance use disorders.

2. The method of claim 1 wherein the compound is selected from the group consisting of

2,3: 4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclobutylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose diethylsulfamate;

2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate;

(S)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate;

(R)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate;

2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate;

2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D -fructopyranose sulfamate;

2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate;

2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate;

(S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate, and the pharmaceutically acceptable salts thereof.

3. The method of claim 1 wherein the compound is selected from the group consisting of (1R,2R,3S,4S)-(1,2:

3,4-di-O-methylethylidenecyclohexan-1,2,3,4-tetrahydroxy-4-yl)methyl sulfamate and (1R,2S,3S,4S)-(3,4-O-methylethylidene-1,2-O-sulfinylcyclohexan-1,2,3,4-tetrahydroxy-4-yl)methyl sulfamate.

4. The method of claim 1 wherein the compound of formula I is topiramate.

5. The method of claim 1, wherein the therapeutically effective amount is of from about 15 to about 2000 mg per day.

6. The method of claim 1, wherein the therapeutically effective amount is of from about 25 to about 750 mg per day.

7. The method of claim 1 wherein the compound is used in conjunction with one or more other drug compounds selected from the group consisting of adrenergics, adrenocortical steroids, adrenocortical suppressants, aldosterone antagonists, amino acids, analeptics, analgesics, anorectic compounds, anorexics, anti-anxiety agents, antidepressants, antihypertensives, anti-inflammatorys, antinauseants, antineutropenics, antiobsessional agents, antiparkinsonians, antipsychotics, appetite suppressants, blood glucose regulators, carbonic anhydrase inhibitors, cardiotonics, cardiovascular agents, choleretics, cholinergics, cholinergic agonists, cholinesterase deactivators, cognition adjuvants, cognition enhancers, hormones, memory adjuvants, mental performance enhancers, mood regulators, neuroleptics, neuroprotectives, psychotropics, relaxants, sedative-hypnotics, serotonin antagonists, serotonin inhibitors, serotonin receptor antagonists, stimulants, thyroid hormones, thyroid inhibitors, thyromimetics, cerebral ischemia agents, vasoconstrictors, and vasodilators.

8. The method of claim 1 wherein the Impulse Control Disorder is an eating disorder and the compound is used in conjunction with one or more other drug compounds selected from the group consisting of serotonin re-uptake inhibitors, antidepressants, psychostimulants, and orlistat.

9. The method of claim 1 wherein the Impulse Control Disorder is a nicotine addiction condition and the compound is used in conjunction with one or more other drug compounds selected from the group consisting of bupropion, serotonin reuptake inhibitors, nicotine, and antidepressants.

10. The method of claim 1 wherein the Impulse Control Disorder is an alcohol abuse/dependence condition and the compound is used in conjunction with one or more other drug compounds selected from the group consisting of naltrexone, serotonin reuptake inhibitors, and other antidepressants.

11. The method of claim 1 wherein the Impulse Control Disorder is a behavioral addiction condition and the compound is used in conjunction with one or more other drug compounds selected from the group consisting of serotonin reuptake inhibitors, lithium, valproic acid or divalproex sodium, other antidepressants, naltrexone, atypical antipsychotics, and other mood stabilizers.

12. The method of claim 1 wherein the Impulse Control Disorder is a paraphilias/sexual addiction condition and the compound is used in conjunction with one or more other drug compounds selected from the group consisting of serotonin reuptake inhibitors, lithium, divalproex sodium/valproic acid, antiandrogen agents, other antidepressants, and other mood stabilizers.

13. A method for treating an Impulse Control Disorder comprising administering to a mammal afflicted with such condition a therapeutically effective amount for treating such condition of a compound of the formula I:

wherein

X is CH₂ or oxygen;

R₁ is hydrogen or alkyl; and

R₂, R₃, R₄ and R₅ are independently hydrogen or lower alkyl and, when X is CH₂, R₄ and R₅ may be alkene groups joined to form a benzene ring and, when X is oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of the following formula (II);

 

wherein

R₆ and R₇ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring;

wherein the Impulse Control Disorder is selected from the group consisting of intermittent explosive disorder (IED), kleptomania, pathological gambling, pyromania, trichotillomania, compulsive buying or shopping, repetitive self-mutilation, nonparaphilic sexual addictions, severe nail biting, compulsive skin picking, personality disorders with impulsive features, attention deficit/hyperactivity disorder, Binge Eating Disorder, anorexia nervosa with binge eating and substance use disorders.

14. A method for treating an Impulse Control Disorder comprising administering to a mammal afflicted with such condition a therapeutically effective amount for treating such condition of a compound of the formula I:

wherein

X is CH₂or oxygen;

R₁ is hydrogen or alkyl; and

R₂, R₃, R₄ and R₅ are independently hydrogen or lower alkyl and, when X is CH₂, R₄ and R₅ may be alkene groups joined to form a benzene ring and, when X is oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of the following formula (II);

 

wherein

R₆ and R₇ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring;

wherein the Impulse Control Disorder is bulimia nervosa.

15. A method for treating an Impulse Control Disorder characterized by binge eating, wherein the Impulse Control Disorder is selected from the group consisting of Binge Eating Disorder, Bulimia Nervosa and Anorexia Nervosa with Binge Eating, said method comprising administering to a human afflicted with such a disorder, a therapeutically effective amount of topiramate in combination with one or more drug compounds selected from the group consisting of serotonin re-uptake inhibitors, antidepressants, psychostimulants, orlistat, and sibutramine.

16. A method for treating an Impulse Control Disorder characterized by binge eating, wherein the Impulse Control Disorder is selected from the group consisting of Binge Eating Disorder, Bulimia Nervosa and Anorexia Nervosa with Binge Eating, said method comprising administering to a human afflicted with such a disorder, a therapeutically effective amount of topiramate in combination with a serotonin re-uptake inhibitor.